» Articles » PMID: 39802185

Deregulation Mechanisms and Therapeutic Opportunities of P53-responsive MicroRNAs in Diffuse Large B-cell Lymphoma

Overview
Journal PeerJ
Date 2025 Jan 13
PMID 39802185
Authors
Affiliations
Soon will be listed here.
Abstract

Here, we have discussed the molecular mechanisms of p53-responsive microRNAs dysregulation in response to genotoxic stress in diffuse large B-cell lymphoma (DLBCL) patients. The role of micro ribonucleic acids (microRNAs) in p53-signaling cellular stress has been studied. MicroRNAs are the small non-coding RNAs, which regulate genes expression at post-transcriptional level. Many of them play a crucial role in carcinogenesis and may act as oncogenes or suppressor of tumor growth. The understanding of the effect of p53-responsive microRNA dysregulation on oncogenesis achieved in recent decades opens wide opportunities for the diagnosis, prediction and of microRNA-based cancer therapy. Development of new bioinformatics tools and databases for microRNA supports DLBCL research. We overview the studies on the role of miRNAs in regulating gene expression associated with tumorigenesis processes, with particular emphasis on their role as tumor growth-suppressing factors. The starting point is a brief description of the classical microRNA biogenesis pathway and the role of p53 in regulating the expression of these molecules. We analyze various molecular mechanisms leading to this dysregulation, including mutations in the gene, DNA methylation, changes in host-genes expression or microRNA gene copy number, mutations in microRNA and microRNA biogenesis genes.

References
1.
Ghosh A, Ranjan N, Jiang L, Ansari A, Degyatoreva N, Ahluwalia S . Fine-tuning miR-21 expression and inhibition of EMT in breast cancer cells using aromatic-neomycin derivatives. Mol Ther Nucleic Acids. 2022; 27:685-698. PMC: 8763640. DOI: 10.1016/j.omtn.2021.12.027. View

2.
Leivonen S, Icay K, Jantti K, Siren I, Liu C, Alkodsi A . MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J. 2017; 7(12):654. PMC: 5802506. DOI: 10.1038/s41408-017-0033-8. View

3.
Zhang Z, Huang Q, Yu L, Zhu D, Li Y, Xue Z . The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies. Front Immunol. 2022; 12:807895. PMC: 8803638. DOI: 10.3389/fimmu.2021.807895. View

4.
Tomaselli S, Bonamassa B, Alisi A, Nobili V, Locatelli F, Gallo A . ADAR enzyme and miRNA story: a nucleotide that can make the difference. Int J Mol Sci. 2013; 14(11):22796-816. PMC: 3856091. DOI: 10.3390/ijms141122796. View

5.
Chim C, Wong K, Leung C, Chung L, Hui P, Chan S . Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med. 2011; 15(12):2760-7. PMC: 4373446. DOI: 10.1111/j.1582-4934.2011.01274.x. View